共 65 条
[1]
Hingorani AD(2013)PROGRESS group. Prognosis research strategy (PROGRESS) 4: stratified medicine research BMJ 346 e5793-57
[2]
Windt DA(2013)European guidance for the diagnosis and management of osteoporosis in postmenopausal women Osteoporos Int 24 23-1441
[3]
Riley RD(2001)Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 1434-1513
[4]
Kanis JA(2005)Sustained non vertebral fragility fracture risk reduction after discontinuation of teriparatide treatment J Bone Miner Res 20 1507-397
[5]
McCloskey EV(2008)FRAX™ and the assessment of fracture probability in men and women from the UK Osteoporos Int 19 385-141
[6]
Johansson H(2007)Clodronate reduces the incidence of fractures in community dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study J Bone Miner Res 22 135-818
[7]
Cooper C(2009)Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double blind, placebo controlled randomised study Osteoporos Int 20 811-54
[8]
Rizzoli R(2009)Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX® Bone 44 49-1486
[9]
Neer RM(2012)Denosumab reduces the risk of all osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX® J Bone Miner Res 27 1480-735
[10]
Arnaud CD(2010)A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX Bone 47 729-2355